Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00825539 · ClinicalTrials.gov registry record · Phase 1
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT00825539 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT00825539, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
Part 1 of the study will assess the enhancement of task-related brain activation (BOLD response) in key brain areas in schizophrenia during the performance of working memory, episodic memory and visual activation tasks as measured by functional magnetic resonance imaging (fMRI) in people with schizophrenia. Part 2 of the study will assess the safety and tolerability of multiple doses of AQW051 in people with schizophrenia.
Interventions
- DRUG Placebo
- DRUG AQW051
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00825539
The ClinicalTrials.gov registry entry for NCT00825539 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00825539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00825539 about?
NCT00825539 is a clinical study titled "Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia". Part 1 of the study will assess the enhancement of task-related brain activation (BOLD response) in key brain areas in schizophrenia during the performance of working memory, episodic memory and visual activation tasks as measured by functional magnetic resonance imaging (fMRI) in people with schizo...
What is the current status of trial NCT00825539?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2009-01. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00825539?
The interventions under investigation include: Placebo (DRUG), AQW051 (DRUG).
Who is sponsoring clinical trial NCT00825539?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.